Multidimensional Early Prediction Score for Drug-Resistant Epilepsy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Achieving favorable postoperative outcomes in patients with drug-resistant epilepsy (DRE) requires early referrals for preoperative examinations. The purpose of this study was to investigate the possibility of a user-friendly early DRE prediction model that is easy for nonexperts to utilize. Methods A two-step genotype analysis was performed, by applying 1) whole-exome sequencing (WES) to the initial test set (n=243) and 2) target sequencing to the validation set (n=311). Based on a multicenter case–control study design using the WES data set, 11 genetic and 2 clinical predictors were selected to develop the DRE risk prediction model. The early prediction scores for DRE (EPS-DRE) was calculated for each group of the selected genetic predictors (EPS-DREgen), clinical predictors (EPS-DREcln), and two types of predictor mix (EPS-DREmix) in both the initial test set and the validation set. Results The multidimensional EPS-DREmix of the predictor mix group provided a better match to the outcome data than did the unidimensional EPS-DREgen or EPS-DREcln. Unlike previous studies, the EPS-DREmix model was developed using only 11 genetic and 2 clinical predictors, but it exhibited good discrimination ability in distinguishing DRE from drug-responsive epilepsy. These results were verified using an unrelated validation set. Conclusions Our results suggest that EPS-DREmix has good performance in early DRE prediction and is a user-friendly tool that is easy to apply in real clinical trials, especially by nonexperts who do not have detailed knowledge or equipment for assessing DRE. Further studies are needed to improve the performance of the EPS-DREmix model.
Abstract
Background and Purpose Achieving favorable postoperative outcomes in patients with drug-resistant epilepsy (DRE) requires early referrals for preoperative examinations. The purpose of this study was to investigate the possibility of a user-friendly early DRE prediction model that is easy for nonexperts to utilize. Methods A two-step genotype analysis was performed, by applying 1) whole-exome sequencing (WES) to the initial test set (n=243) and 2) target sequencing to the validation set (n=311). Based on a multicenter case–control study design using the WES data set, 11 genetic and 2 clinical predictors were selected to develop the DRE risk prediction model. The early prediction scores for DRE (EPS-DRE) was calculated for each group of the selected genetic predictors (EPS-DREgen), clinical predictors (EPS-DREcln), and two types of predictor mix (EPS-DREmix) in both the initial test set and the validation set. Results The multidimensional EPS-DREmix of the predictor mix group provided a better match to the outcome data than did the unidimensional EPS-DREgen or EPS-DREcln. Unlike previous studies, the EPS-DREmix model was developed using only 11 genetic and 2 clinical predictors, but it exhibited good discrimination ability in distinguishing DRE from drug-responsive epilepsy. These results were verified using an unrelated validation set. Conclusions Our results suggest that EPS-DREmix has good performance in early DRE prediction and is a user-friendly tool that is easy to apply in real clinical trials, especially by nonexperts who do not have detailed knowledge or equipment for assessing DRE. Further studies are needed to improve the performance of the EPS-DREmix model.
참고문헌 (50)
- Fiest KM, "Prevalence and incidence of epilepsy : a systematic review and metaanalysis of international studies", Neurology, 88, pp.296~303 (2017)
- Chen Z, "Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs : a 30-year longitudinal cohort study", JAMA Neurol, 75, pp.279~286 (2018)
- Kwan P, "Early identification of refractory epilepsy", N Engl J Med, 342, pp.314~319 (2000)
- McCagh J, "Epilepsy, psychosocial and cognitive functioning", Epilepsy Res, 86, pp.1~14 (2009)
- Mohanraj R, "Mortality in adults with newly diagnosed and chronic epilepsy : a retrospective comparative study", Lancet Neurol, 5, pp.481~487 (2006)
- Lawn ND, "Injuries due to seizures in persons with epilepsy : a population-based study", Neurology, 63, pp.1565~1570 (2004)
- Begley CE, "The direct cost of epilepsy in the United States : a systematic review of estimates", Epilepsia, 56, pp.1376~1387 (2015)
- Wiebe S, "A randomized, controlled trial of surgery for temporal-lobe epilepsy", N Engl J Med, 345, pp.311~318 (2001)
- Spencer SS, "Initial outcomes in the multicenter study of epilepsy surgery", Neurology, 61, pp.1680~1685 (2003)
- Engel J Jr, "Practice parameter : temporal lobe and localized neocortical resections for epilepsy : report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons", Neurology, 60, pp.538~547 (2003)
- Engel J Jr, "Early surgical therapy for drug-resistant temporal lobe epilepsy : a randomized trial", JAMA, 307, pp.922~930 (2012)
- Jeha LE, "Predictors of outcome after temporal lobectomy for the treatment of intractable epilepsy", Neurology, 66, pp.1938~1940 (2006)
- Dwivedi R, "Surgery for drug-resistant epilepsy in children", N Engl J Med, 377, pp.1639~1647 (2017)
- Bjellvi J, "Epilepsy duration and seizure outcome in epilepsy surgery : a systematic review and meta-analysis", Neurology, 93, pp.e159~e166 (2019)
- Perry MS, "Surgical versus medical treatment for refractory epilepsy : outcomes beyond seizure control", Epilepsia, 54, pp.2060~2070 (2013)
- Meguins LC, "Shorter epilepsy duration is associated with better seizure outcome in temporal lobe epilepsy surgery", Arq Neuropsiquiatr, 73, pp.212~217 (2015)
- Pelliccia V, "Early and late epilepsy surgery in focal epilepsies associated with long-term epilepsy-associated tumors", J Neurosurg, 127, pp.1147~1152 (2017)
- Ramantani G, "Epilepsy surgery in children and adolescents", Neurol Int Open, 1, pp.E86~E97 (2017)
- 고아라, "Factors associated with seizure and cognitive outcomes after epilepsy surgery for low-grade epilepsy-associated neuroepithelial tumors in children", Clinical and Experimental Pediatrics, 63(5), pp.171~177 (2020), 대한소아청소년과학회[DOI]
- Gilliam F, "Patient-oriented outcome assessment after temporal lobectomy for refractory epilepsy", Neurology, 53, pp.687~694 (1999)
- Berg AT, "How long does it take for partial epilepsy to become intractable?", Neurology, 60, pp.186~190 (2003)
- Benbadis SR, "Epilepsy surgery, delays and referral patterns-are all your epilepsy patients controlled?", Seizure, 12, pp.167~170 (2003)
- Choi H, "Evaluation of duration of epilepsy prior to temporal lobe epilepsy surgery during the past two decades", Epilepsy Res, 86, pp.224~227 (2009)
- Haneef Z, "Referral pattern for epilepsy surgery after evidence-based recommendations : a retrospective study", Neurology, 75, pp.699~704 (2010)
- Engel J Jr, "The timing of surgical intervention for mesial temporal lobe epilepsy : a plan for a randomized clinical trial", Arch Neurol, 56, pp.1338~1341 (1999)
- Dlugos DJ, "The early identification of candidates for epilepsy surgery", Arch Neurol, 58, pp.1543~1546 (2001)
- Berg AT, "Understanding the delay before epilepsy surgery : who develops intractable focal epilepsy and when?", CNS Spectr, 9, pp.136~144 (2004)
- Hakimi AS, "A survey of neurologists’ views on epilepsy surgery and medically refractory epilepsy", Epilepsy Behav, 13, pp.96~101 (2008)
- Tang F, "Drug-resistant epilepsy : multiple hypotheses, few answers", Front Neurol, 8, pp.301~ (2017)
- Sisodiya SM, "Mechanisms of antiepileptic drug resistance", Curr Opin Neurol, 16, pp.197~201 (2003)
- Gibson G, "Rare and common variants : twenty arguments", Nat Rev Genet, 13, pp.135~145 (2012)
- Golan D, "Measuring missing heritability : inferring the contribution of common variants", Proc Natl Acad Sci U S A, 111, pp.E5272~E5281 (2014)
- Fuchsberger C, "The genetic architecture of type 2 diabetes", Nature, 536, pp.41~47 (2016)
- Khera AV, "Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations", Nat Genet, 50, pp.1219~1224 (2018)
- Mavaddat N, "Polygenic risk scores for prediction of breast cancer and breast cancer subtypes", Am J Hum Genet, 104, pp.21~34 (2019)
- Choi SW, "Tutorial : a guide to performing polygenic risk score analyses", Nat Protoc, 15, pp.2759~2772 (2020)
- Kang KW, "Genetic characteristics of non-familial epilepsy", PeerJ, 7, pp.e8278~ (2019)
- Kwan P, "Definition of drug resistant epilepsy : consensus proposal by the ad hoc Task Force of the ILAE Commission on therapeutic strategies", Epilepsia, 51, pp.1069~1077 (2010)
- Wang J, "Epilepsy-associated genes", Seizure, 44, pp.11~20 (2017)
- Lascano AM, "Seizures and epilepsies due to channelopathies and neurotransmitter receptor dysfunction : a parallel between genetic and immune aspects", Mol Syndromol, 7, pp.197~209 (2016)
- Zhang Z, "Somatic variants in new candidate genes identified in focal cortical dysplasia type II", Epilepsia, 61, pp.667~678 (2020)
- Kim MK, "Association of restless legs syndrome variants in Korean patients with restless legs syndrome", Sleep, 36, pp.1787~1791 (2013)
- Kwan P, "Drug-resistant epilepsy", N Engl J Med, 365, pp.919~926 (2011)
- Kalilani L, "The epidemiology of drug-resistant epilepsy : a systematic review and metaanalysis", Epilepsia, 59, pp.2179~2193 (2018)
- Trinka E, "A definition and classification of status epilepticus--Report of the ILAE Task Force on classification of status epilepticus", Epilepsia, 56, pp.1515~1523 (2015)
- Muller MP, "Can routine laboratory tests discriminate between severe acute respiratory syndrome and other causes of community-acquired pneumonia?", Clin Infect Dis, 40, pp.1079~1086 (2005)
- Fluss R, "Estimation of the Youden Index and its associated cutoffpoint", Biom J, 47, pp.458~472 (2005)
- Schurz H, "Evaluating the accuracy of imputation methods in a five-way admixed population", Front Genet, 10, pp.34~ (2019)
- Rudolph A, "Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium", Int J Epidemiol, 47, pp.526~536 (2018)
- Martin AR, "Human demographic history impacts genetic risk prediction across diverse populations", Am J Hum Genet, 100, pp.635~649 (2017)
